Data and implication based comparison of two chronic myeloid leukemia models

R. A. Everett, Y. Zhao, K. B. Flores, Yang Kuang

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Chronic myeloid leukemia, a disorder of hematopoietic stem cells, is currently treated using targeted molecular therapy with imatinib. We compare two models that describe the treatment of CML, a multi-scale model (Model 1) and a simple cell competition model (Model 2). Both models describe the competition of leukemic and normal cells, however Model 1 also describes the dynamics of BCR-ABL, the oncogene targeted by imatinib, at the sub-cellular level. Using clinical data, we analyze the differences in estimated parameters between the models and the capacity for each model to predict drug resistance. We found that while both models fit the data well, Model 1 is more biologically relevant. The estimated parameter ranges for Model 2 are unrealistic, whereas the parameter ranges for Model 1 are close to values found in literature. We also found that Model 1 predicts long-term drug resistance from patient data, which is exhibited by both an increase in the proportion of leukemic cells as well as an increase in BCR-ABL/ABL%. Model 2, however, is not able to predict resistance and accurately model the clinical data. These results suggest that including sub-cellular mechanisms in a mathematical model of CML can increase the accuracy of parameter estimation and may help to predict long-term drug resistance.

Original languageEnglish (US)
Pages (from-to)1501-1518
Number of pages18
JournalMathematical Biosciences and Engineering
Volume10
Issue number5-6
DOIs
StatePublished - Oct 1 2013

Keywords

  • Cancer modeling
  • Chronic myeloid leukemia
  • Clinical data
  • Drug resistance

ASJC Scopus subject areas

  • Modeling and Simulation
  • Agricultural and Biological Sciences(all)
  • Computational Mathematics
  • Applied Mathematics

Fingerprint Dive into the research topics of 'Data and implication based comparison of two chronic myeloid leukemia models'. Together they form a unique fingerprint.

  • Cite this